GTB-3550

DB18494InvestigationalProtein Based Therapies

GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form...

Mechanism: Pharmacologically active on Myeloid cell surface antigen CD33 and Low affinity immunoglobulin gamma Fc region receptor III-A
Curator reviewed
Also known as: single chain recombinant trispecific killer engager consistent of anti-CD16 scFV spliced to anti-CD33 scFV with a modified IL-15 linker
Code names: GTB-3550

Resolves to

Compound

UNIIE5GE91Q5FX

Targets

P20138CD33P08637FCGR3A

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with GTB-3550, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account